Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease?
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 12707450.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Patients with mild cognitive impairment (MCI) were assessed, and a metabolic profile associated with conversion to AD at 18-month follow-up was sought. As compared with nonconverters (n = 10), converters (n = 7) had lower fluorodeoxyglucose uptake in the right temporoparietal cortex (p = 0.02, corrected for cluster size), without individual overlap. Awaiting replication in an independent sample, these findings suggest that among patients with MCI, fluorodeoxyglucose PET may accurately identify rapid converters.
Medical subject headings
- Alzheimer Disease
- Tomography, Emission-Computed